Company Description
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications.
The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial.
It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Rα for the treatment of Type 2 allergic diseases.
Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jul 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 196 |
| CEO | Michael Henderson |
Contact Details
Address: Building 17, Suite 102b Waltham, Massachusetts 02453 United States | |
| Phone | 650 394 5230 |
| Website | apogeetherapeutics.com |
Stock Details
| Ticker Symbol | APGE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001974640 |
| CUSIP Number | 432705309 |
| ISIN Number | US4327053090 |
| Employer ID | 93-4958665 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Thomas Henderson M.D. | Chief Executive Officer and Director |
| Jane Pritchett V. Henderson | Chief Financial Officer |
| Dr. Carl Linden Dambkowski M.D. | Chief Medical Officer |
| Noel Kurdi | Vice President of Investor Relations |
| Matthew Batters J.D. | Chief Legal Officer and Corporate Secretary |
| Emily Cox | Vice President and Head of People |
| Dr. Rebecca Dabora Ph.D. | Chief Development Officer |
| Wendy Aspden-Curran | Senior Vice President of Clinical Operations |
| Dr. Drew Badger Ph.D. | Senior Vice President and Head of Regulatory Affairs and Toxicology |
| Monica Forbes | Senior Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2025 | 144 | Filing |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 144 | Filing |
| Mar 3, 2025 | 8-K | Current Report |
| Mar 3, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 3, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 5, 2025 | 144 | Filing |
| Feb 3, 2025 | 8-K | Current Report |
| Jan 8, 2025 | 144 | Filing |